Ustekinumab for treating active psoriatic arthritis

  • Technology appraisal guidance
  • TA340
  • Published: 
  • Last updated: 

Review decision – July 2018

Decision to move the existing guidance to the static list

We would like to update you on the decision made regarding the review of the existing guidance on TA340; Ustekinumab for treating active psoriatic arthritis.

No new evidence is available that would require an update of this guidance. The guidance has been incorporated into the NICE guideline on spondyloarthritis in over 16s: diagnosis and management (NG65).

NICE’s Guidance Executive has decided to proceed with this proposal without consultation.

Consequently TA340 will move to the ‘static list’ of technology appraisals.

Review decision paper

This page was last updated: